Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Incretin hormones, including glucagon-like peptide-1 (GLP-1), a target for diabetes mellitus (DM) treatment, are associated with cardioprotection. As dipeptidyl-peptidase IV (DPP-IV) inhibition increases plasma GLP-1 levels in vivo, we investigated the cardioprotective effects of the DPP-IV inhibitor vildagliptin in a murine heart failure (HF) model. We induced transverse aortic constriction (TAC) in C57BL/6J mice, simulating pressure-overloaded cardiac hypertrophy and HF. TAC or sham-operated mice were treated with or without vildagliptin. An intraperitoneal glucose tolerance test revealed that blood glucose levels were higher in the TAC than in sham-operated mice, and these levels improved with vildagliptin administration in both groups. Vildagliptin increased plasma GLP-1 levels in the TAC mice and ameliorated TAC-induced left ventricular enlargement and dysfunction. Vildagliptin palliated both myocardial apoptosis and fibrosis in TAC mice, demonstrated by histological, gene and protein expression analyses, and improved survival rate on day 28 (TAC with vildagliptin, 67.5%; TAC without vildagliptin, 41.5%; P < 0.05). Vildagliptin improved cardiac dysfunction and overall survival in the TAC mice, both by improving impaired glucose tolerance and by increasing GLP-1 levels. DPP-IV inhibitors represent a candidate treatment for HF patients with or without DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction
Vasan, R. S., Larson, S., Benjamin, E. J., Evans, J. C., Reiss, C. K., & Levy, D. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00118-7 · Cited by 1,331
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Wei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450 · cited 1×
“GLP-1 is thought to possess cardioprotective properties because of the following three reasons: 1) GLP-1 receptors localize to cardiomyocytes and endothelial cells (3, 57); 2) activation of GLP-1 receptors increases phosphoinositide 3 (PI3)-kinase, serine/threonine protein kinase Akt (Akt), and extracellular signal-re…”
BackgroundTrevaskis, J. L., Griffin, P. S., Wittmer, C., Neuschwander-Tetri, B. A., Brunt, E. M., Dolman, C. S., Erickson, M. R., Napora, J., Parkes, D. G., & Roth, J. D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00476.2011 · Cited by 277 · cited 1×
“A recent report (55) demonstrated amelioration of nonalcoholic steatohepatitis in mice by an analog of exenatide, a GLP-1 receptor agonist, supporting the antifibrotic effect of GLP-1 in murine hearts.”
BackgroundSuskin, N. (2000) · European Heart Journal · doi:10.1053/euhj.1999.2043 · Cited by 271 · cited 1×
“Either glucose abnormalities or diabetes commonly exists in patients with HF, but as previously reported, patients with diabetes have no worse outcome of HF (50).”
BackgroundLIAO, Y., TAKASHIMA, S., MAEDA, N., OUCHI, N., KOMAMURA, K., SHIMOMURA, I., HORI, M., MATSUZAWA, Y., FUNAHASHI, T., & KITAKAZE, M. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.04.018 · Cited by 236 · cited 1×
“We previously reported that HF is associated with impaired glucose tolerance in mice and dogs, and that correction of impaired glucose tolerance with voglibose or metformin reduces HF severity (26, 27, 41).”
BackgroundSelf-citationNikolaidis, L. A., Doverspike, A., Hentosz, T., Zourelias, L., Shen, Y.-T., Elahi, D., & Shannon, R. P. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073890 · Cited by 137 · cited 1×
“GLP-1 analogs reportedly ameliorate not only DM but also HF and myocardial ischemia (15, 33, 34, 48, 59), suggesting that DPP-IV inhibitors function cardioprotectively.”
BackgroundEgstrup, M., Kistorp, C. N., Schou, M., Hofsten, D. E., Moller, J. E., Tuxen, C. D., & Gustafsson, I. (2013) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jes165 · Cited by 21
Cited by
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Kanasaki, K., Shi, S., Kanasaki, M., He, J., Nagai, T., Nakamura, Y., Ishigaki, Y., Kitada, M., Srivastava, S. P., & Koya, D. (2014) · Diabetes · doi:10.2337/db13-1029 · Cited by 359
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 304
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Metadata
- Authors
- Takahashi, A., Asakura, M., Ito, S., Min, K.-D., Shindo, K., Yan, Y., Liao, Y., Yamazaki, S., Sanada, S., Asano, Y., Ishibashi-Ueda, H., Takashima, S., Minamino, T., Asanuma, H., Mochizuki, N., & Kitakaze, M.
- Venue
- American Journal of Physiology-Heart and Circulatory Physiology
- Publisher
- American Physiological Society
- Published
- 2013-05-15
- Volume
- 304
- Issue
- 10
- Pages
- H1361-H1369
- ISSN
- 0363-6135 (ISSN-L)
- 1522-1539
- OpenAlex
- W2146355144
- Cited by
- 60
- References
- 10
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. https://app.cochat.ai/papers/10.1152/ajpheart.00454.2012
- The paper
- Takahashi, A., Asakura, M., Ito, S., Min, K.-D., Shindo, K., Yan, Y., Liao, Y., Yamazaki, S., Sanada, S., Asano, Y., Ishibashi-Ueda, H., Takashima, S., Minamino, T., Asanuma, H., Mochizuki, N., & Kitakaze, M. (2013). Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. American Journal of Physiology-Heart and Circulatory Physiology. https://doi.org/10.1152/ajpheart.00454.2012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.